DENTSPLY SIRONA Future Growth
Future criteria checks 4/6
DENTSPLY SIRONA is forecast to grow earnings and revenue by 67.2% and 1.7% per annum respectively. EPS is expected to grow by 75.2% per annum. Return on equity is forecast to be 20.2% in 3 years.
Key information
67.2%
Earnings growth rate
75.23%
EPS growth rate
Medical Equipment earnings growth | 12.8% |
Revenue growth rate | 1.7% |
Future return on equity | 20.25% |
Analyst coverage | Good |
Last updated | 13 May 2025 |
Recent future growth updates
Recent updates
DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) CEO Might Not Expect Shareholders To Be So Generous This Year
May 15Earnings Beat: DENTSPLY SIRONA Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
May 11DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
May 09Revamped E-commerce And Imaging Products Will Secure Success
Strategic divestment of Wellspect HealthCare aims to unlock value and improve net margins, leveraging its growth and profitability.Here's Why DENTSPLY SIRONA (NASDAQ:XRAY) Has A Meaningful Debt Burden
Apr 29DENTSPLY SIRONA (NASDAQ:XRAY) Has More To Do To Multiply In Value Going Forward
Apr 08DENTSPLY SIRONA (NASDAQ:XRAY) Has Affirmed Its Dividend Of $0.16
Mar 18Weak Results And Poor Growth Prospects Have Dentsply Sirona Deep In The Street's Doghouse
Mar 05Benign Growth For DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Underpins Its Share Price
Feb 13DENTSPLY SIRONA (NASDAQ:XRAY) Has A Somewhat Strained Balance Sheet
Jan 08Is Now An Opportune Moment To Examine DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Dec 21DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Shares Could Be 40% Below Their Intrinsic Value Estimate
Dec 03Dentsply Sirona: No Change To Operating Mechanics Despite Extensive Review
Nov 27DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Nov 11DENTSPLY SIRONA (NASDAQ:XRAY) Hasn't Managed To Accelerate Its Returns
Oct 13DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 25Is It Time To Consider Buying DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Sep 05Is There An Opportunity With DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) 21% Undervaluation?
Aug 18Returns On Capital At DENTSPLY SIRONA (NASDAQ:XRAY) Have Hit The Brakes
Jul 11A Tough Macro Environment Makes Dentsply Sirona's Turnaround Even Harder
Jul 02Insufficient Growth At DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Hampers Share Price
Jun 11We Think DENTSPLY SIRONA (NASDAQ:XRAY) Can Stay On Top Of Its Debt
May 24Dentsply Sirona: I'm Buying The Pullback In This Medtech Leader
Apr 24Are Investors Undervaluing DENTSPLY SIRONA Inc. (NASDAQ:XRAY) By 47%?
Apr 22There's No Escaping DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Muted Revenues
Mar 10Here's Why DENTSPLY SIRONA (NASDAQ:XRAY) Has A Meaningful Debt Burden
Feb 16DENTSPLY SIRONA (NASDAQ:XRAY) Has More To Do To Multiply In Value Going Forward
Jan 29DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Shares Could Be 28% Below Their Intrinsic Value Estimate
Jan 11Is It Too Late To Consider Buying DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Nov 25These 4 Measures Indicate That DENTSPLY SIRONA (NASDAQ:XRAY) Is Using Debt Extensively
Nov 06Returns On Capital At DENTSPLY SIRONA (NASDAQ:XRAY) Paint A Concerning Picture
Oct 15An Intrinsic Calculation For DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Suggests It's 46% Undervalued
Sep 18DENTSPLY SIRONA (NASDAQ:XRAY) Has A Pretty Healthy Balance Sheet
Jul 31The Returns At DENTSPLY SIRONA (NASDAQ:XRAY) Aren't Growing
Jul 09A Look At The Fair Value Of DENTSPLY SIRONA Inc. (NASDAQ:XRAY)
Jun 20When Should You Buy DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Jun 02Investors Don't See Light At End Of DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Tunnel
May 15Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2027 | 3,834 | 262 | 420 | 455 | 12 |
12/31/2026 | 3,729 | 208 | 345 | 409 | 16 |
12/31/2025 | 3,640 | 136 | 216 | 269 | 17 |
3/31/2025 | 3,719 | -908 | 278 | 443 | N/A |
12/31/2024 | 3,793 | -910 | 281 | 461 | N/A |
9/30/2024 | 3,900 | -413 | 365 | 534 | N/A |
6/30/2024 | 3,896 | -185 | 364 | 527 | N/A |
3/31/2024 | 3,940 | -95 | 279 | 423 | N/A |
12/31/2023 | 3,965 | -132 | 228 | 377 | N/A |
9/30/2023 | 3,936 | -214 | 218 | 359 | N/A |
6/30/2023 | 3,936 | -1,025 | 198 | 334 | N/A |
3/31/2023 | 3,931 | -1,038 | 259 | 403 | N/A |
12/31/2022 | 3,922 | -950 | 368 | 517 | N/A |
9/30/2022 | 4,042 | -816 | 439 | 597 | N/A |
6/30/2022 | 4,135 | 345 | 499 | 660 | N/A |
3/31/2022 | 4,174 | 368 | 545 | 701 | N/A |
12/31/2021 | 4,231 | 411 | 515 | 657 | N/A |
9/30/2021 | 4,207 | 401 | 584 | 712 | N/A |
6/30/2021 | 4,062 | 370 | 634 | 748 | N/A |
3/31/2021 | 3,491 | 179 | 617 | 708 | N/A |
12/31/2020 | 3,339 | -73 | 562 | 649 | N/A |
9/30/2020 | 3,371 | -80 | 575 | 672 | N/A |
6/30/2020 | 3,438 | -48 | 524 | 623 | N/A |
3/31/2020 | 3,957 | 84 | 479 | 594 | N/A |
12/31/2019 | 4,022 | 256 | 516 | 639 | N/A |
9/30/2019 | 3,977 | 162 | 397 | 536 | N/A |
6/30/2019 | 3,944 | 105 | 337 | 502 | N/A |
3/31/2019 | 3,976 | -1,053 | 291 | 474 | N/A |
12/31/2018 | 3,986 | -1,011 | N/A | 500 | N/A |
9/30/2018 | 4,018 | -1,663 | N/A | 527 | N/A |
6/30/2018 | 4,098 | -1,601 | N/A | 565 | N/A |
3/31/2018 | 4,049 | -1,529 | N/A | 575 | N/A |
12/31/2017 | 3,993 | -1,550 | N/A | 602 | N/A |
9/30/2017 | 3,899 | -793 | N/A | 595 | N/A |
6/30/2017 | 3,844 | -791 | N/A | 584 | N/A |
3/31/2017 | 3,873 | 365 | N/A | 645 | N/A |
12/31/2016 | 3,745 | 430 | N/A | 563 | N/A |
9/30/2016 | 3,420 | 382 | N/A | 467 | N/A |
6/30/2016 | 3,115 | 374 | N/A | 474 | N/A |
3/31/2016 | 2,791 | 312 | N/A | 433 | N/A |
12/31/2015 | 2,674 | 251 | N/A | 497 | N/A |
9/30/2015 | 2,722 | 277 | N/A | 564 | N/A |
6/30/2015 | 2,782 | 268 | N/A | 551 | N/A |
3/31/2015 | 2,849 | 314 | N/A | 561 | N/A |
12/31/2014 | 2,923 | 323 | N/A | 560 | N/A |
9/30/2014 | 2,957 | 313 | N/A | 527 | N/A |
6/30/2014 | 2,953 | 317 | N/A | 506 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XRAY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.8%).
Earnings vs Market: XRAY is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: XRAY is expected to become profitable in the next 3 years.
Revenue vs Market: XRAY's revenue (1.7% per year) is forecast to grow slower than the US market (8.5% per year).
High Growth Revenue: XRAY's revenue (1.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: XRAY's Return on Equity is forecast to be high in 3 years time (20.2%)
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/05/20 10:52 |
End of Day Share Price | 2025/05/20 00:00 |
Earnings | 2025/03/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DENTSPLY SIRONA Inc. is covered by 34 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Jeffrey Johnson | Baird |
Lawrence Marsh | Barclays |
Michael Petusky | Barrington Research Associates, Inc. |